This technology is a nanoparticle that encapsulates γ-secretase complex inhibitors, which can be administered for treatment of NASH.
The prevalence of nonalcoholic steatohepatitis (NASH) has been increasing in recent years, yet treatment options remain limited. The connection between type 2 diabetes mellitus and NASH has been extensively studied, with recent discoveries demonstrating that activation of the cell signaling pathway known as Notch leads to poorer outcomes for NASH. Therefore, inhibition of Notch is postulated as a method of NASH treatment. While inhibitors of Notch do improve NASH-related symptoms, the side effects of these inhibitors prevent their usage, suggesting that a targeted approach is necessary.
This technology utilizes nanoparticles for specific delivery of γ-secretase complex inhibitors (GSI), a type of Notch inhibitor that has been extensively studied. These nanoparticles allow for localized delivery of the GSI to the liver while sparing other tissues. As a result, the side effects that were previously seen with general administration of GSIs, such as intestinal metaplasia, are abrogated, while maintaining the benefits of the GSIs. When administered in an in vivo model, the nanoparticles are able to reverse NASH-induced liver fibrosis.
This technology has been validated in mice models.
Utpal Pajvani, M.D., Ph.D.
Li Qiang, Ph.D.
IR CU20227
Licensing Contact: Cynthia Lang
